keyword
MENU ▼
Read by QxMD icon Read
search

PD-L1 immunohistochemistry

keyword
https://www.readbyqxmd.com/read/28534943/bu-fei-decoction-attenuates-the-tumor-associated-macrophage-stimulated-proliferation-migration-invasion-and-immunosuppression-of-non-small-cell-lung-cancer-partially-via-il-10-and-pd-l1-regulation
#1
Lina Pang, Shuyan Han, Yanna Jiao, Shantong Jiang, Xiran He, Pingping Li
Macrophages play a pivotal role in tumor microenvironment. Bu-Fei Decoction (BFD) is a classical formula of traditional Chinese medicine (TCM) to alleviate lung cancer related symptoms, whether it has antitumor effect or could influence cancer microenvironment deserves further study. The aim of the present study was to examine the antitumor effect of BFD on non-small cell lung cancer (NSCLC), and to investigate the underlying mechanisms through tumor associated macrophages (TAMs). M2-polarized TAMs were induced by Phorbol 12-myristate 13-acetate (PMA) and interleukin 4 (IL-4)...
May 19, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28524003/targeting-the-programmed-cell-death-1-pathway-in-genitourinary-tumors-current-progress-and-future-perspectives
#2
Rodolfo Montironi, Liang Cheng, Holger Moch, Antonio Lopez-Beltran, Marina Scarpelli, Francesco Massari, Michelangelo Fiorentino, Chiara Ciccarese, Michael Koch, Hristos Z Kaimakliotis, Lisha Wang, Roberto Pili, Steven A Mann
Immune checkpoint inhibitors have revolutionized the treatment many malignancies with over a dozen new United States Food and Drug Administration (FDA) approvals in the past six years. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors, gathering prognostic and predictive information about FDA-indicated tumors is prudent. PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC and urothelial carcinoma...
May 18, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28507813/deep-exploration-of-the-immune-infiltrate-and-outcome-prediction-in-testicular-cancer-by-quantitative-multiplexed-immunohistochemistry-and-gene-expression-profiling
#3
Peter J Siska, Romany A N Johnpulle, Alice Zhou, Jennifer Bordeaux, Ju Young Kim, Bashar Dabbas, Naveen Dakappagari, Jeffrey C Rathmell, W Kimryn Rathmell, Alicia K Morgans, Justin M Balko, Douglas B Johnson
Platinum-based chemotherapy is usually curative for patients with testicular germ cell tumors (TGCT), but a subset of patients experience disease progression and poor clinical outcomes. Here, we tested whether immune profiling of TGCT could identify novel prognostic markers and therapeutic targets for this patient cohort. We obtained primary and metastatic TGCT samples from one center. We performed immune profiling using multiplexed fluorescence immunohistochemistry (FIHC) for T-cell subsets and immune checkpoints, and targeted gene expression profiling (Nanostring nCounter Immune panel)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28507801/the-novel-negative-checkpoint-regulator-vista-is-expressed-in-gastric-carcinoma-and-associated-with-pd-l1-pd-1-a-future-perspective-for-a-combined-gastric-cancer-therapy
#4
Christine Böger, Hans-Michael Behrens, Sandra Krüger, Christoph Röcken
A combined blockade of V-domain Ig suppressor of T-cell activation (VISTA) and PD-1 is a promising new cancer treatment option, which was efficient in murine tumor models and is currently tested in first phase I studies. Here, we analyzed the VISTA expression in a large and well-characterized gastric cancer (GC) cohort on 464 therapy-naive GC samples and 14 corresponding liver metastases using immunohistochemistry. Staining results were correlated with clinico-pathological characteristics, genetic alterations and survival...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28496107/cd163-cd204-tumor-associated-macrophages-contribute-to-t-cell-regulation-via-interleukin-10-and-pd-l1-production-in-oral-squamous-cell-carcinoma
#5
Keigo Kubota, Masafumi Moriyama, Sachiko Furukawa, Haque A S M Rafiul, Yasuyuki Maruse, Teppei Jinno, Akihiko Tanaka, Miho Ohta, Noriko Ishiguro, Masaaki Yamauchi, Mizuki Sakamoto, Takashi Maehara, Jun-Nosuke Hayashida, Shintaro Kawano, Tamotsu Kiyoshima, Seiji Nakamura
Tumor-associated macrophages (TAMs) promote cancer cell proliferation, invasion, and metastasis by producing various mediators. Although preclinical studies demonstrated that TAMs preferentially express CD163 and CD204, the TAM subsets in oral squamous cell carcinoma (OSCC) remain unknown. In this study, we examined the expression and role of TAM subsets in OSCC. Forty-six patients with OSCC were analyzed for expression of TAMs in biopsy samples by immunohistochemistry. We examined TAM subsets and their production of immune suppressive molecules (IL-10 and PD-L1) in peripheral blood mononuclear cells from three OSCC patients by flow cytometry...
May 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28493410/expression-and-prognostic-significance-of-programmed-death-protein-1-and-programmed-death-ligand-1-and-cytotoxic-t-lymphocyte-associated-molecule-4-in-hepatocellular-carcinoma
#6
Hyeyoon Chang, Wonkyung Jung, Aeree Kim, Han Kyeom Kim, Wan Bae Kim, Ji Hoon Kim, Baek-Hui Kim
Hepatocellular carcinoma (HCC) is one of the most common malignancies and causes of death worldwide. In this study, we assessed the correlation between clinicopathologic factors with programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) expressions. Furthermore, we analyzed the prognostic significance of these proteins in a subgroup of patients. We retrospectively evaluated the PD-1, PD-L1, and CTLA-4 expressions in 294 HCC tissue microarray samples using immunohistochemistry...
May 11, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28488345/patterns-of-pd-1-pd-l1-and-pd-l2-expression-in-pediatric-solid-tumors
#7
Navin Pinto, Julie R Park, Erin Murphy, Jennifer Yearley, Terri McClanahan, Lakshmanan Annamalai, Douglas S Hawkins, Erin R Rudzinski
BACKGROUND: Significant antitumor effects have been observed in a variety of malignancies via blockade of immune checkpoints. Interaction of programmed death 1 (PD-1) with its ligands PD-L1 and PD-L2 suppresses T-cell function and restricts immune-mediated tumor killing. We examined expression of these proteins in children with solid tumors, as expression may serve as biomarkers of response to this class of drugs. METHODS: Sections cut from formalin-fixed paraffin-embedded (FFPE) tissue blocks were processed and evaluated for PD-1, PD-L1, and PD-L2 by immunohistochemistry (IHC) as well as by mRNA expression...
May 10, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28488168/the-therapeutic-candidate-for-immune-checkpoint-inhibitors-elucidated-by-the-status-of-tumor-infiltrating-lymphocytes-tils-and-programmed-death-ligand-1-pd-l1-expression-in-triple-negative-breast-cancer-tnbc
#8
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Mitsugu Yamamoto, Masako Sato, Ken-Ichi Watanabe, Katsushige Yamashiro, Masato Takahashi
BACKGROUND: The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor for triple negative breast cancer (TNBC). Recent studies have shown that programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1) is expressed on T lymphocytes or tumor cells modulating antitumor immunity. The regulation of immune checkpoints between tumor cells and T lymphocytes may serve as a target for improvement of TNBC prognosis. We investigated TILs and PD-L1 status in TNBCs before or after preoperative systemic therapy (PST) to elucidate the clinical significance of PD-L1 expression...
May 9, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28487100/differential-expression-of-pd-l1-in-high-grade-t1-vs-muscle-invasive-bladder-carcinoma-and-its-prognostic-implications
#9
Stephanie A M Wankowicz, Lillian Werner, Anna Orsola, Jesse Novak, Michaela Bowden, Toni K Choueiri, Inés de Torres, Juan Morote, Gordon J Freeman, Sabina Signoretti, Joaquim Bellmunt
PURPOSE: PD-1 ligand (PD-L1) is expressed on both tumor cells (TCs) and tumor immune cell infiltrates (TIMC). In metastatic bladder cancer, increased TIMC PD-L1 positivity (PD-L1+) was correlated with better overall survival, however, in high grade T1 bladder tumors (HGT1) PD-L1+ on TCs and TIMCs, and correlation with outcome or pathological features remain unknown. MATERIALS AND METHODS: Formalin-fixed paraffin embedded (FFPE) tumor samples from 140 clinically annotated HGT1patients (pts) were retrieved...
May 6, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28484456/expression-of-tlr4-in-non-small-cell-lung-cancer-is-associated-with-pd-l1-and-poor-prognosis-in-patients-receiving-pulmonectomy
#10
Kaiyuan Wang, Jian Wang, Feng Wei, Ning Zhao, Fan Yang, Xiubao Ren
Currently, the effect of inflammation on tumorigenesis and progression has been widely noted. As a member of pattern recognition receptors, toll-like receptor 4 (TLR4) plays a pivotal role in tumor immune microenvironment and has been increasingly investigated. In the present study, we evaluated TLR4 expression and its association with programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) tissues and assessed the predicting value of TLR4 on postoperative outcome. A total of 126 NSCLC patients receiving complete pulmonary resection and systematic lymph node dissection between April 2008 and August 2014 were enrolled...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28476872/integrative-analysis-identifies-a-novel-axl-pi3-kinase-pd-l1-signaling-axis-associated-with-radiation-resistance-in-head-and-neck-cancer
#11
Heath D Skinner, Uma Giri, Liang P Yang, Manish Kumar, Ying Liu, Michael D Story, Curtis R Pickering, Lauren A Byers, Michelle D Williams, Jing Wang, Li Shen, Suk Y Yoo, You Hong Fan, David P Molkentine, Beth M Beadle, Raymond E Meyn, Jeffrey N Myers, John V Heymach
Purpose: The primary cause of death due to head and neck squamous cell carcinoma (HNSCC) is local treatment failure. The goal of this study was to examine this phenomenon using an unbiased approach.Experimental Design: We utilized human papilloma virus (HPV)-negative cell lines rendered radiation-resistant (RR) via repeated exposure to radiation, a panel of HPV-negative HNSCC cell lines and three cohorts of HPV-negative HNSCC tumors (n = 68, 97, and 114) from patients treated with radiotherapy and subjected to genomic, transcriptomic, and proteomic analysis...
May 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28472759/pd-1-and-pd-l1-expression-in-132-recurrent-nasopharyngeal-carcinoma-the-correlation-with-anemia-and-outcomes
#12
Yajuan Zhou, Jingjing Miao, Haijun Wu, Hao Tang, Jing Kuang, Xiaoyi Zhou, Yi Peng, Desheng Hu, Dingbo Shi, Wuguo Deng, Xinyue Cao, Chong Zhao, Conghua Xie
The expression of Programmed death-1 (PD-1) / programmed death-ligand 1 (PD-L1) has been reported to be reliable prognostic factors in various malignances including primary nasopharyngeal carcinoma (NPC). However, the exact role of PD-1/PD-L1 in recurrent NPC remains unclear. In this study, we aimed to investigate the relationship between the expression of PD-1 / PD-L1 and the clinical-pathology as well the outcomes of recurrent NPC patients (n = 132). The expression of PD-1 and PD-L1 was measured by immunohistochemistry staining...
April 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28470686/tumor-cell-expression-of-immune-inhibitory-molecules-and-tumor-infiltrating-lymphocyte-count-predict-cancer-specific-survival-in-pancreatic-and-ampullary-cancer
#13
Kostandinos Sideras, Katharina Biermann, Kevin Yap, Shanta Mancham, Patrick P C Boor, Bettina E Hansen, Hans J A Stoop, Maikel P Peppelenbosch, Casper H van Eijck, Stefan Sleijfer, Jaap Kwekkeboom, Marco J Bruno
Understanding the mechanisms of immune resistance in pancreatic and ampullary cancers is crucial for the development of suitable biomarkers and effective immunotherapeutics. Our aim was to examine the expression of the immune inhibiting molecules PD-L1, Galectin-9, HVEM, IDO and HLA-G, as well as CD8+ and FoxP3+ tumor infiltrating lymphocytes (TIL), in pancreatic and ampullary cancers, and to relate their individual, as well as their combined expression, to cancer survival. Tumor tissue from 224 patients with resected pancreatic (n = 148) and ampullary (n = 76) cancer was used to construct tissue-microarrays...
May 3, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28468947/phase-i-trial-of-intratumoral-injection-of-ccl21-gene-modified-dendritic-cells-in-lung-cancer-elicits-tumor-specific-immune-responses-and-cd8-t-cell-infiltration
#14
Jay Moon M Lee, Mi-Heon Lee, Edward Garon, Jonathan W Goldman, Ramin Salehi-Rad, Felicita E Baratelli, Dorthe Schaue, Gerald Wang, Fran Rosen, Jane Yanagawa, Tonya C Walser, Ying Lin, Stacy J Park, Sharon Adams, Francesco M Marincola, Paul C Tumeh, Fereidoun Abtin, Robert Suh, Karen L Reckamp, Gina Lee, William D Wallace, Sarah Lee, Gang Zeng, David A Elashoff, Sherven Sharma, Steven M Dubinett
PURPOSE: A phase I study was conducted to determine safety, clinical efficacy, and anti-tumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral (IT) administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the CCL21 gene (Ad-CCL21-DC). We evaluated safety and tumor antigen-specific immune responses following in situ vaccination (ClinicalTrials.gov: NCT01574222). EXPERIMENTAL DESIGN: Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 x 106, 5 x 106, 1 x 107, or 3 x 107 dendritic cells/injection) by CT- or bronchoscopic-guided IT injections (days 0 and 7)...
May 3, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28463396/t-cell-infiltration-and-clonality-correlate-with-programmed-cell-death-protein-1-and-programmed-death-ligand-1-expression-in-patients-with-soft-tissue-sarcomas
#15
Seth M Pollack, Qianchuan He, Jennifer H Yearley, Ryan Emerson, Marissa Vignali, Yuzheng Zhang, Mary W Redman, Kelsey K Baker, Sara Cooper, Bailey Donahue, Elizabeth T Loggers, Lee D Cranmer, Matthew B Spraker, Y David Seo, Venu G Pillarisetty, Robert W Ricciotti, Benjamin L Hoch, Terrill K McClanahan, Erin Murphy, Wendy M Blumenschein, Steven M Townson, Sharon Benzeno, Stanley R Riddell, Robin L Jones
BACKGROUND: Patients with metastatic sarcomas have poor outcomes and although the disease may be amenable to immunotherapies, information regarding the immunologic profiles of soft tissue sarcoma (STS) subtypes is limited. METHODS: The authors identified patients with the common STS subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), well-differentiated/dedifferentiated liposarcoma, and myxoid/round cell liposarcoma. Gene expression, immunohistochemistry for programmed cell death protein (PD-1) and programmed death-ligand 1 (PD-L1), and T-cell receptor Vβ gene sequencing were performed on formalin-fixed, paraffin-embedded tumors from 81 patients...
May 2, 2017: Cancer
https://www.readbyqxmd.com/read/28461179/immune-characterization-of-the-programmed-death-receptor-pathway-in-high-risk-prostate%C3%A2-cancer
#16
Wesley Baas, Svetlana Gershburg, Danuta Dynda, Kristin Delfino, Kathy Robinson, Daotai Nie, Jennifer Holmes Yearley, Shaheen Alanee
BACKGROUND: Programmed cell death-1 (PD-1), a T-cell inhibitory receptor, and its ligand, PD-L1, have been reported to be expressed in many tumor types, and this expression has led to the development of many drugs targeting the PD-1 pathway. The objective of this study was to determine the expression of PD-1 and PD-L1 in high-grade prostate cancer tissues, and correlate the expression with disease and patient characteristics. MATERIALS AND METHODS: Immunohistochemistry for PD-1 (CD279), PD-L1 (B7-H1), and CD3 was performed and scored from 0 to 5 on prostatectomy/biopsy tissue samples taken from 25 men with high-grade prostate cancer...
April 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28460468/pd-l1-expression-and-its-relationship-with-oncogenic-drivers-in-non-small-cell-lung-cancer-nsclc
#17
Liyan Jiang, Xinying Su, Tianwei Zhang, Xiaolu Yin, Meizhuo Zhang, Haihua Fu, Hulin Han, Yun Sun, Lili Dong, Jialin Qian, Yanhua Xu, Xuan Fu, Paul R Gavine, Yanbin Zhou, Kun Tian, Jiaqi Huang, Dong Shen, Haiyi Jiang, Yihong Yao, Baohui Han, Yi Gu
In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC.Tumor samples from 297 NSCLC patients, including 156 adenocarcinomas (AD) and 129 squamous cell carcinomas (SCC), were analyzed using immunohistochemistry, immunofluorescence, sequencing and fluorescence in situ hybridization...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28460462/the-prognostic-role-of-immune-checkpoint-markers-programmed-cell-death-protein-1-pd-1-and-programmed-death-ligand-1-pd-l1-in-a-large-multicenter-prostate-cancer-cohort
#18
Nora Ness, Sigve Andersen, Mehrdad Rakaee Khanehkenari, Cecilie V Nordbakken, Andrej Valkov, Erna-Elise Paulsen, Yngve Nordby, Roy M Bremnes, Tom Donnem, Lill-Tove Busund, Elin Richardsen
Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28460011/the-immune-microenvironment-of-hpv-negative-oral-squamous-cell-carcinoma-from-never-smokers-and-never-drinkers-patients-suggests-higher-clinical-benefit-of-ido1-and-pd1-pd-l1-blockade
#19
J-P Foy, C Bertolus, M-C Michallet, S Deneuve, R Incitti, N Bendriss-Vermare, M-A Albaret, S Ortiz-Cuaran, E Thomas, A Colombe, C Py, N Gadot, J-P Michot, J Fayette, A Viari, B Van den Eynde, P Goudot, M Devouassoux-Shisheboran, A Puisieux, C Caux, P Zrounba, S Lantuejoul, P Saintigny
Background: : Never-smokers and never-drinkers patients (NSND) suffering from oral squamous cell carcinoma (OSCC) are epidemiologically different from smokers drinkers (SD). We therefore hypothesized that they harbored distinct targetable molecular alterations. Patients and methods: Data from The Cancer Genome Atlas (TCGA) (discovery set), Gene Expression Omnibus and Centre Léon Bérard (CLB) (3 validation sets) with available gene expression profiles of HPV-negative OSCC from NSND and SD were mined...
April 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28455983/pd-l1-expression-as-poor-prognostic-factor-in-patients-with-non-squamous-non-small-cell-lung-cancer
#20
Cuiling Zhou, Jianjun Tang, Huanhuan Sun, Xiaobin Zheng, Zhanyu Li, Tiantian Sun, Jie Li, Shuncong Wang, Xiuling Zhou, Hongliu Sun, Zhibin Cheng, Hongyu Zhang, Haiqing Ma
OBJECTIVES: The role of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), especially according to histologic type, remains controversial. The purpose of this study was to assess PD-L1 expression and its association with overall survival (OS) and clinicopathologic characteristics in NSCLC. MATERIAL AND METHODS: Formalin-fixed paraffin-embedded specimens were obtained from 108 patients with surgically resected primary NSCLC. PD-L1 expression was assessed via immunohistochemistry using a histochemistry score system...
April 11, 2017: Oncotarget
keyword
keyword
116890
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"